Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer called poorly differentiated neuroendocrine carcinoma that started outside the lung.
- Your cancer cannot be removed with surgery or has spread to other parts of the body.
- You have not had prior treatment for advanced disease, except you may have had one round of chemo with a platinum drug and etoposide.
- You have not taken immune checkpoint inhibitors (like PD-1 or PD-L1 blockers) for this cancer before.
- You are generally well enough to carry out daily activities (performance status 0–2).
- Your kidney, liver, and blood counts meet certain levels as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (LBL-024) combined with standard chemotherapy for people with advanced EP-NEC, a rare type of neuroendocrine tumor. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy for people with neuroendocrine carcinoma that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
Hear when a new Advanced Extrapulmonary Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.